Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma.

PURPOSE Intestinal trefoil factor (ITF) is a marker of intestinal differentiation that may also play a role in cancer cell biology by inhibiting cell adhesion, promoting cell invasion, and blocking apoptosis. Gastric adenocarcinomas can arise through a process of intestinalization, but no study has yet comprehensively examined the expression of ITF in gastric cancer or correlated ITF expression with clinical outcome in any cancer type. EXPERIMENTAL DESIGN Patients (209) with primary gastric adenocarcinoma were evaluated for ITF expression by immunohistochemistry. Results of immunostaining were correlated with clinicopathological variables and overall survival. RESULTS In normal gastric mucosa, ITF expression was absent, whereas areas of intestinal metaplasia revealed strong ITF expression by goblet cells. A portion of gastric cancers (55%) demonstrated ITF expression. Women were more likely than men to express ITF in gastric cancers. However, in men, the expression of ITF correlated with aggressive phenotype of tumors (advanced stage, infiltrative growth pattern, and positive lymph nodes). Multivariate analysis revealed that expression of ITF was associated with a poor prognosis, independent of tumor stage. CONCLUSIONS This is the first study to correlate ITF expression with clinicopathological features or outcome in any cancer type. ITF expression in gastric cancer exhibited a curious gender-associated relationship, being more frequently expressed in tumors of women, but associated with more aggressive pathological features in men. The poor prognosis of patients with ITF-positive gastric cancers further implicates ITF in cancer cell biology.

[1]  F. May,et al.  Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells , 1997, The Journal of pathology.

[2]  L. Thim,et al.  Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. , 1994, The Journal of clinical investigation.

[3]  W. Bodmer,et al.  Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells , 1998 .

[4]  L. Villani,et al.  Expression of pepsinogen II in gastric cancer. Its relationship to local invasion and lymph node metastases , 1988, Cancer.

[5]  R. Poulsom,et al.  Experimental ulceration leads to sequential expression of spasmolytic polypeptide, intestinal trefoil factor, epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach , 1995, The Journal of pathology.

[6]  P. Chambon,et al.  Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[7]  R. Lathe,et al.  Expression of the breast cancer associated gene pS2 and the pancreatic spasmolytic polypeptide gene (hSP) in diffuse type of stomach carcinoma. , 1991, European journal of cancer.

[8]  M. Sobrinho-Simões,et al.  pS2 protein expression in gastric carcinoma. An immunohistochemical and immunoradiometric study. , 1996, European journal of cancer.

[9]  R. Poulsom,et al.  hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. McCrea,et al.  Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[11]  H. Aburatani,et al.  Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. , 2001, Cancer research.

[12]  M. Tatematsu,et al.  Gastric and Intestinal Phenotypic Expression of Human Stomach Cancers as Revealed by Pepsinogen lmmunohistochemistry and Mucin Histochemistry , 1990, Acta pathologica japonica.

[13]  Y. Kato,et al.  Pathological studies of human gastric cancer. , 1982, Acta pathologica japonica.

[14]  R. Lathe,et al.  Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. , 1988, Science.

[15]  H. Itoh,et al.  Expression of intestinal trefoil factor mRNA is downregulated during progression of colorectal carcinomas. , 1997, Journal of clinical pathology.

[16]  胃癌研究会.  Japanese classification of gastric carcinoma , 1995 .

[17]  M. Tatematsu,et al.  Histogenesis of Human Stomach Cancers Based on Assessment of Differentiation , 1992, Journal of clinical gastroenterology.

[18]  P. Chambon,et al.  Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. , 1982, Nucleic acids research.

[19]  G. Stamp,et al.  Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co‐expressed in normal, hyperplastic, and neoplastic human breast epithelium , 1997, The Journal of pathology.

[20]  M. Bennett,et al.  Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. , 1991, British Journal of Cancer.

[21]  P. Chambon,et al.  Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues , 1990, The Journal of pathology.

[22]  L. Thim,et al.  Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. , 1995, Gastroenterology.

[23]  L. Thim.  A new family of growth factor‐like peptides ‘Trefoil’ disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spasmolysins) , 1989, FEBS letters.

[24]  L. Villani,et al.  Characterization of four main cell types in gastric cancer: foveolar, mucopeptic, intestinal columnar and goblet cells. An histopathologic, histochemical and ultrastructural study of "early" and "advanced" tumours. , 1987, Pathology, research and practice.

[25]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[26]  L. Thim,et al.  Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. , 1996, Gastroenterology.

[27]  M. Tatematsu,et al.  Intestinalization of gastric signet ring cell carcinomas with progression , 1997, Virchows Archiv.

[28]  G. Stamp,et al.  Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. , 1992, Scandinavian journal of gastroenterology. Supplement.

[29]  P. Chambon,et al.  Breast cancer-associated protein pS2 expression in tumors of the biliary tract. , 1991, The American journal of gastroenterology.

[30]  K. Botzenhart,et al.  Trefoil factor family domain peptides in the human respiratory tract , 2000, The Journal of pathology.

[31]  R. Poulsom,et al.  Molecular aspects of restitution: functions of trefoil peptides. , 1996, The Yale journal of biology and medicine.

[32]  M. Tatematsu,et al.  Phenotypic shift in human differentiated gastric cancers from gastric to intestinal epithelial cell type during disease progression , 1998, Gastric Cancer.

[33]  R. Poulsom,et al.  Primary mucinous carcinomas of the skin express TFF1, TFF3, estrogen receptor, and progesterone receptors. , 1998, The American journal of surgical pathology.

[34]  D. Taupin,et al.  Conserved expression of intestinal trefoil factor in the human colonic adenoma-carcinoma sequence. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[35]  D. Taupin,et al.  Augmented Intestinal Trefoil Factor (TFF3) and Loss of pS2 (TFF1) Expression Precedes Metaplastic Differentiation of Gastric Epithelium , 2001, Laboratory Investigation.

[36]  O. Kojima,et al.  Localization of estrogen receptors in gastric cancer using immunohistochemical staining of monoclonal antibody , 1991, Cancer.

[37]  T. Wang,et al.  Spasmolytic polypeptide: a trefoil peptide secreted by rat gastric mucous cells. , 1994, Gastroenterology.

[38]  H. S. Kim,et al.  Mapping of a new target region of allelic loss at 21q22 in primary gastric cancers. , 2000, Cancer letters.

[39]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[40]  R. Poulsom,et al.  Trefoil peptides: mitogens, motogens, or mirages? , 1997, Journal of clinical gastroenterology.

[41]  N. Wright,et al.  Trefoil factor family domain peptides , 1997, Virchows Archiv.

[42]  M. Fishman,et al.  Impaired Defense of Intestinal Mucosa in Mice Lacking Intestinal Trefoil Factor , 1996, Science.

[43]  R. Poulsom,et al.  Trefoil factor expression in normal and diseased human salivary glands. , 2000, Human pathology.

[44]  D. Taupin,et al.  Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B. Sands,et al.  Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. , 1993, The Journal of biological chemistry.

[46]  S. Dooley,et al.  The three human trefoil genes TFF1, TFF2, and TFF3 are located within a region of 55 kb on chromosome 21q22.3. , 1997, Genomics.

[47]  P. Chambon,et al.  Gastric Mucosa Abnormalities and Tumorigenesis in Mice Lacking the pS2 Trefoil Protein , 1996, Science.

[48]  M. Mareel,et al.  Induction of scattering and cellular invasion by trefoil peptides in src‐ and RhoA‐transformed kidney and colonic epithelial cells , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  L. Thim,et al.  Rolling in the clover: trefoil factor family (TFF)‐domain peptides, cell migration and cancer , 1997, FEBS letters.

[50]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[51]  W. Jagla,et al.  Co‐localization of TFF3 peptide and oxytocin in the human hypothalamus , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  Y. Fujimori,et al.  Proliferative markers in gastric carcinoma and organoid differentiation. , 1995, Human pathology.

[53]  Y. Chen,et al.  Transcription factor NF-kappaB signals antianoikic function of trefoil factor 3 on intestinal epithelial cells. , 2000, Biochemical and biophysical research communications.